United States· US:0054-0883_e135daff-043e-4944-baf8-dfea510cec60
dicyclomine hydrochloride
A dicycloverine product containing dicyclomine hydrochloride, registered in United States by Hikma Pharmaceuticals USA Inc.. The same ATC class is registered in 3 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Dicycloverine is registered in 3 of 19 countries.
Countries holding a registration under ATC A03AA07 (dicycloverine), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 1 of them publish a price we can compare per daily dose
Dicycloverine · ATC A03AA07
3 / 19 countries
- Canada
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of dicycloverine costs, country by country.
Normalised to the WHO defined daily dose (80 mg), so markets compare like for like.
- United States: $0.62 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Dicycloverine · price per daily dose (80 mg)
USD · FX 28 Sept 2026
- US United States$0.62 (acquisition cost)
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- DICYCLOMINE HYDROCHLORIDE
- Manufacturer
- Hikma Pharmaceuticals USA Inc.
- Country
- United States (US)
- ATC code
- A03AA07
- ATC class
- Dicycloverine
- Defined daily dose
- 80 mg, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc110054-0883-25
- ndc110054-0883-31
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
389 interactions on record for dicycloverine.
Graded by severity as the source publishes them — 6 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Dicycloverine · interactions on record
389 records
- 6 severe
- 194 moderate
- 17 minor
- 172 info
Most severe, free to view
- Potassium chlorideA12BA01severe
- Potassium citrateA12BA02severe
- Potassium chlorideB05XA01severe
- TopiramatN02CX12severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Dicycloverine in 2 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Dicycloverine, Dicycloverine Focus Pharmaceuticals
- Latvia · Trigan-Sp
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f70252cc-8b42-421d-af7c-0c0dd18bd28f GET /v1/drugs/f70252cc-8b42-421d-af7c-0c0dd18bd28f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "10",
"substance": "DICYCLOMINE HYDROCHLORIDE",
"productndc": "0054-0883",
"dosage_form": "CAPSULE",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "ANDA040204",
"marketing_category": "ANDA"
}See everything about dicycloverine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.